RxDoctor Payments Data

Antonio Muina, MD

Hematology & Oncology · Miami, FLNPI 1386631562

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $244 of the $329 with a category attached, or 74.1%. 8 manufacturers reported payments, led by Seagen Inc. at 38.0% of the total. Reporting peaked in 2020 at $152 and has fallen 69.8% since, to $46 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.

$329in general payments, 2019–2025

Across 8 payments — averaging $41.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$125
  • Johnson & Johnson$85
  • Olympus America Inc.$46
  • Sumitomo Pharma America, Inc.$17
  • Merck$16
  • Bayer$15
  • plus $24 from 2 others
$348,455in research payments, 2019–2025

Across 96 payments — averaging $3629.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$174K
  • Exelixis Inc.$130K
  • E.r. Squibb & Sons, L.L.C.$34K
  • Eisai Inc.$11K
  • Merck$27

What the payments were for

  • Food & beverage$24474%
  • Education$8526%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Seagen Inc.1$125
Johnson & Johnson1$85
Olympus America Inc.1$46
Sumitomo Pharma America, Inc.1$17
Merck1$16
Bayer1$15
180 Medical, Inc.1$13
Pfizer1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$329 in reported general payments places this provider in the 15th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$118,510
Medicare patients
381
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide33$453,388
WeliregBelzutifan14$416,442
XtandiEnzalutamide30$415,760
CabometyxCabozantinib S-Malate13$329,898
LenvimaLenvatinib Mesylate12$292,524
OrgovyxRelugolix68$178,674
Abiraterone Acetate235$107,461
EliquisApixaban57$36,580
Everolimus17$11,235
Prednisone280$1,027
Bicalutamide42$854
Silodosin11$512
Tamsulosin Hcl26$337
Dexamethasone12$258
Gabapentin19$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$15$453,38833 claims
MerckWelireg$16$416,44214 claims
Sumitomo Pharma America, Inc.Orgovyx$17$178,67468 claims
PfizerEliquis$11$36,58057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →